

Ref: GLL/BSE/2023-24/Aug

Date: August 14, 2023

To  
The General Manager,  
Corporate Relations Department,  
**BSE Limited**  
Phiroze Jeejeebhoy Towers,  
Dalal Street, **Mumbai - 400001.**  
Maharashtra State, India.  
**Script Code: 531739**

To  
The Listing Manager,  
**The Ahmedabad Stock Exchange Limited**  
A-2, Kamdhenu Complex, Opp. Sahajanand  
College, 120 Feet Ring Road, Panjara Pol,  
Ambawadi, **Ahmedabad - 380015.**  
Gujarat State, India.  
**Script Code:**

To  
**The Calcutta Stock Exchange Limited,**  
#7, Lyons Range, Murgighata,  
Dalhousie, **Kolkata - 700001,**  
West Bengal State, India.  
**Script Code: 26178**

Dear Sir/Madam,

**Sub: Outcome of the Board Meeting of Gennex Laboratories Limited -  
Scrip Code: 531739/GENNEX**

**Ref: Regulation 33 of the SEBI (LODR) Regulations, 2015.**

In just concluded Meeting of Board of Directors, the Board Approved and considered the following items:

1. Unaudited (Standalone and Consolidated) Financial Statements for the Quarter ended June 30, 2023 (annexed herewith);
2. Limited review reports from the Statutory Auditor on Unaudited (Standalone and Consolidated) Financial Statements for the Quarter ended June 30, 2023 (annexed here with).


We hereby submit that the Board Meeting had commenced at 04:30 PM and concluded at 06:00 PM.

This intimation is also uploaded on the Company website: [www.gennexlab.com](http://www.gennexlab.com)

We request you to take the above information on record and acknowledge the receipt of the same.

Thanking you,

Yours faithfully  
**For Gennex Laboratories Limited**

  
**Dinesh Kumar Kejriwal**  
Company Secretary & Compliance Officer



**Gennex Laboratories Limited**



**Statement of Standalone and Consolidated Unaudited Financial Results for the Quarter Ended 30th June, 2023**

S.No.	PARTICULARS	Standalone						Consolidated						
		Quarter ended		Year ended		Quarter ended		Year ended		Quarter ended		Year ended		
		30.06.2023 (Unaudited)	31.03.2023 (Audited)	30.06.2022 (Unaudited)	31.03.2023 (Audited)	30.06.2023 (Unaudited)	31.03.2023 (Audited)	30.06.2022 (Unaudited)	31.03.2023 (Audited)	30.06.2022 (Unaudited)	31.03.2023 (Audited)			
1	Income	1414.46	1815.19	1393.73	6509.81	1648.84	1865.68	1393.73	6560.29					
	Revenue from Operations	3.38	159.17	57.36	340.35	3.38	214.17	57.36	395.35					
	Other Income	1417.84	1974.36	1451.09	6850.16	1652.23	2079.85	1451.09	6955.64					
	<b>Total Income</b>													
2	Expenses	862.82	1105.41	1240.42	4691.08	946.59	1105.40	1240.42	4691.08					
(a)	Cost of material consumed	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00					
(b)	Purchase of stock-in-trade	-310.79	-3.85	-423.22	-699.75	-445.13	-3.85	-423.22	-699.75					
(c)	Changes in stock-in-trade and Work in Progress and stock in trade	184.18	197.70	185.86	770.71	245.43	214.22	185.86	787.23					
(d)	Employees Cost	20.23	19.77	17.89	74.44	64.81	37.27	17.89	91.94					
(e)	Depreciation	30.31	50.87	26.40	123.09	73.00	63.16	26.40	135.38					
(f)	Finance Cost	286.57	388.77	303.09	1289.48	395.28	411.76	303.09	1312.47					
(g)	Other Expenses													
	<b>Total Expenses</b>	<b>1073.32</b>	<b>1758.66</b>	<b>1350.44</b>	<b>6249.04</b>	<b>1279.98</b>	<b>1827.96</b>	<b>1350.44</b>	<b>6318.34</b>					
3	Total Profit before exceptional Items & Tax.	344.52	215.70	100.65	601.12	372.25	251.89	100.65	637.30					
4	Exceptional items	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00					
5	Total profit before tax	344.52	215.70	100.65	601.12	372.25	251.89	100.65	637.30					
6	Tax expense for earlier years	0.00	0.00	0.00	-2.28	0.00	0.00	0.00	-2.28					
7	Tax expense for current years	-87.30	-62.28	-25.33	-157.00	-87.30	-62.28	-25.33	-157.00					
8	Current tax	0.00	14.06	0.00	14.06	0.00	14.06	0.00	14.06					
9	Deferred Tax	-87.30	-48.22	-25.33	-145.22	-87.30	-48.22	-25.33	-145.22					
10	Total Tax Expenses	257.23	167.48	75.32	455.90	284.95	203.67	75.32	492.08					
11	Net profit (Loss)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00					
12	Share of profit (loss) of associates and joint ventures accounted for using equity method													
13	Total Profit (loss) for period	257.23	167.48	75.32	455.90	284.95	203.67	75.32	492.08					
14	Other comprehensive income net of taxes		2.36		2.36		127.36		127.36					
15	Total Comprehensive income for the period		169.84		458.26		331.03		619.44					
16	Total profit or loss, attributable to parent													
17	Profit or loss, attributable to owners of parent													
18	Total Comprehensive income for the period attributable to owners of parent													
19	Total comprehensive income for the period attributable to owners of parent non controlling interests													
20	Details of equity share capital													
21	Paid up equity share capital	1766.43	1766.43	1265.03	1766.43	1766.43	1766.43	1265.03	1766.43					
22	Face value of equity share capital	0.00001	0.00001	0.00001	0.00001	0.00001	0.00001	0.00001	0.00001					
23	Earnings per share													
24	- Basic	0.146	0.096	0.096	0.259	0.161	0.161	0.060	0.351					
25	- Diluted	0.146	0.096	0.096	0.259	0.161	0.161	0.060	0.351					





Notes to the results:

- 1 The above unaudited financial results have been reviewed by the Committee of it meeting held on 14.08.2023 and the same were approved and taken on record by the Board of Directors at its meeting held on the same day.
- 2 The Statutory Auditors of the Company have carried out the Limited review of the above unaudited financial results for the Quarter ended June 30, 2023.
- 3 The above results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (IND-AS) prescribed u/s 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
- 4 The management has assessed the Identification of reportable segments in accordance with the requirement of the Ind AS 108 Primary segment and believes that the Company has only one reportable segment namely "Bulk Drugs, Biotech Products and Intermediates". Previous period's figures have been rearranged/regrouped wherever necessary.
- 5 Adjustment of actuarial valuation in respect of compliance with Accounting Standard- IAS-19-'Employee Benefits' is to be done at the year end.
- 6 The quarterly unaudited financial results for the Quarter ended June 30, 2023 are available on the Company's Website i.e; www.gennexlab.com and also available on BSE website i.e; www.bseindia.com.

Place: Hyderabad  
Date: 14.08.2023



For and on behalf of the Board  
For Gennex Laboratories Limited

T.M. Gopalakrishnan  
Whole Time Director  
DIN # 03137458




# Gennex Laboratories Limited

## Segment Reporting (Country Wise)

The following table shows the distribution of the Company's revenue based on the location of the  
(Rs. In Lakhs)

Particulars	Quarterly			Yearly
	30-Jun-23	31-Mar-23	30-Jun-22	31-Mar-23
Algeria			1.65	1.65
Argentina				
Bangladesh	20.35	16.56	6.15	31.62
Belgium				
Brazil	2.24			
Bolivia				
Colombia	4.35	10.1	220.28	46.22
Cuba				126.86
Ecuador				
Egypt		139.56	103.89	573.32
El Salvador	34.25	33.83	34.36	92.06
France			3.51	
Gernmany	29.59	2.21	2.09	80.65
Guatemala	23.79		50.99	117.51
<b>India</b>	<b>1037.93</b>	<b>977.41</b>	<b>827.58</b>	<b>3802.81</b>
Iran		14.76		68.85
Israel				
Jordan				
Mexico				5.03
Nicaragua				
Panama City				
Peru		25.8	48.92	190
Riyad				6.35
Russia	5			4.56
Saudi Arabia	7.41	14.63		29.76
Spain	27.01	90.48		419.49
Switzerland				6.9
Turkey	1.79		2.03	4.84
Uruguay	1.12		2.83	11.51
Vietnam	219.63	489.85	89.45	889.82
Yeman				
	<b>1414.46</b>	<b>1815.19</b>	<b>1393.73</b>	<b>6509.81</b>

For Gennex Laboratories Limited

  
T.M. Gopalakrishnan  
Whole-time Directors  
DIN #03137458



Date: 14-08-2023

Place: Hyderabad



**Limited Review report on Unaudited Standalone Quarterly and year to date financial results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015.**

To  
The Board of Directors,  
Gennex Laboratories Limited,  
Hyderabad.

We have reviewed the accompanying Statement of Unaudited Standalone financial results of **Gennex Laboratories Limited** for the Quarter ended June 30, 2023 ("the statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended.

This statement is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliances with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data, thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as stated in paragraph 3 above nothing has come to our attention, except as stated below, that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

The Balances of Current Assets, Other Non-Current Assets, Current Liabilities, Non-Current Liabilities, Other Non-Current Liabilities & Other Current Liabilities are subject to confirmations/reconciliations. Advances has been paid/received to/from various parties; the details, confirmations/reconciliations/purpose are yet to be provided.

The impact of the above is unascertainable. Subject to stated above, our conclusion on the Statement is not modified.

**For PPKG & Co.**  
Chartered Accountants  
FRN No. 009655S



*Girdhari Lal Toshniwal*

**Girdhari Lal Toshniwal**  
(Partner)

M. No.: 205140

UDIN: 23205140BQUNJS5571

**Place:** Hyderabad

**Date:** 14-08-2023



**Limited Review Report On Consolidated Unaudited Quarterly and year to date financial results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

To  
The Board of Directors,  
Gennex Laboratories Limited,  
Hyderabad.

We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of **Gennex Laboratories Limited** ("the Company") and its share of the net profit after tax and total comprehensive income of its subsidiary for the quarter ended June 30, 2023, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. Attention is drawn to the fact that the consolidated figures corresponding quarter ended June 30, 2023 as reported in these financial results have been approved by the Company's Board of Directors, but have not been subjected to review.

This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act, and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.



The Statement includes the results of **Deccan Remedies Limited. (Subsidiary Company).**

Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standard specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

The Balances of Current Assets, Other Non-Current Assets, Current Liabilities, Non-Current Liabilities, Other Non-Current Liabilities & Other Current Liabilities are subject to confirmations/reconciliations. Advances has been paid/received to/from various parties; the details, confirmations/reconciliations/purpose are yet to be provided.

The impact of above matters is unascertainable. Our Conclusion is not modified in respect of these matter


The accompanying unaudited consolidated financial results includes unaudited interim financial results and other unaudited financial information in respect of 1 Subsidiary, which have been reviewed by other auditors, whose interim financial results excluding consolidation eliminations reflect total revenues of Rs. 234.38 lakhs, total net Profit after tax of Rs. 27.72 lakhs and total comprehensive Profit of Rs. 0.00 lakhs, for the quarter ended June 30, 2023 as considered in the unaudited consolidated financial results. These unaudited financial results and other unaudited financial information have been approved and furnished to us by the management.

Our conclusion, in so far as it relates to the affairs of this subsidiary, is based solely on such unaudited financial results and other unaudited financial information. According to the information and explanations given to us by the Management, these interim financial results are not material to the Group. Our conclusion on the Statement is not modified in respect of the above matter.

**For PPKG & Co**

Chartered Accountants

FRN No. 009655S

  
**Girdhari Lal Toshniwal**

(Partner)

M. No.: 205140

UDIN: 28205140BQVUNJT4883



**Place:** Hyderabad

**Date:** 14-08-2023